| 51 |
26086967 | APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells. | 2015 Jun 18 |
4 |
| 52 |
26269716 | Informative gene network for chemotherapy-induced peripheral neuropathy. | 2015 |
2 |
| 53 |
26334096 | A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer. | 2015 Oct 13 |
1 |
| 54 |
24463159 | TP53 K351N mutation-associated platinum resistance after neoadjuvant chemotherapy in patients with advanced ovarian cancer. | 2014 Mar |
2 |
| 55 |
25142144 | A three-microRNA signature predicts responses to platinum-based doublet chemotherapy in patients with lung adenocarcinoma. | 2014 Sep 15 |
1 |
| 56 |
25250341 | Multiple analytical approaches demonstrate a complex relationship of genetic and nongenetic factors with cisplatin- and carboplatin-induced nephrotoxicity in lung cancer patients. | 2014 |
1 |
| 57 |
25482940 | Polymorphisms of p53 and MDM2 genes are associated with severe toxicities in patients with non-small cell lung cancer. | 2014 |
1 |
| 58 |
22331493 | Sodium arsenite ± hyperthermia sensitizes p53-expressing human ovarian cancer cells to cisplatin by modulating platinum-DNA damage responses. | 2012 May |
4 |
| 59 |
22333583 | Retained platinum uptake and indifference to p53 status make novel transplatinum agents active in platinum-resistant cells compared to cisplatin and oxaliplatin. | 2012 Mar 1 |
1 |
| 60 |
22590594 | NOXA-induced alterations in the Bax/Smac axis enhance sensitivity of ovarian cancer cells to cisplatin. | 2012 |
1 |
| 61 |
23285001 | Synergistic role between p53 and JWA: prognostic and predictive biomarkers in gastric cancer. | 2012 |
2 |
| 62 |
23936624 | A texaphyrin-oxaliplatin conjugate that overcomes both pharmacologic and molecular mechanisms of cisplatin resistance in cancer cells. | 2012 |
1 |
| 63 |
21792013 | Expression of ERCC1, p53, and class III β-tubulin do not reveal chemoresistance in endometrial cancer: results from an immunohistochemical study. | 2011 Aug |
1 |
| 64 |
21863213 | The p53 upregulated modulator of apoptosis (PUMA) chemosensitizes intrinsically resistant ovarian cancer cells to cisplatin by lowering the threshold set by Bcl-x(L) and Mcl-1. | 2011 |
1 |
| 65 |
21927014 | Platinum-(IV)-derivative satraplatin induced G2/M cell cycle perturbation via p53-p21(waf1/cip1)-independent pathway in human colorectal cancer cells. | 2011 Nov |
1 |
| 66 |
22075440 | Nuclear survivin expression is a positive prognostic factor in taxane-platinum-treated ovarian cancer patients. | 2011 Nov 10 |
1 |
| 67 |
22331725 | TP53 gene status and human papilloma virus infection in response to platinum plus taxane-based chemotherapy of epithelial ovarian carcinomas. | 2011 Oct-Dec |
1 |
| 68 |
19499188 | The effect of cellular environment and p53 status on the mode of action of the platinum derivative LA-12. | 2010 Aug |
1 |
| 69 |
19609560 | The role of p53 as a surrogate marker for chemotherapeutical responsiveness in ovarian cancer. | 2010 Jan |
1 |
| 70 |
19854294 | Integrated genomics of chemotherapy resistant ovarian cancer: a role for extracellular matrix, TGFbeta and regulating microRNAs. | 2010 Jan |
1 |
| 71 |
20025464 | DNA damage and p53-mediated growth arrest in human cells treated with platinum nanoparticles. | 2010 Jan |
1 |
| 72 |
20047843 | Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer. | 2010 Sep |
1 |
| 73 |
20101229 | Alternative splicing of p53 and p73: the novel p53 splice variant p53delta is an independent prognostic marker in ovarian cancer. | 2010 Apr 1 |
1 |
| 74 |
20562210 | Metabolic approach to the enhancement of antitumor effect of chemotherapy: a key role of acetyl-L-carnitine. | 2010 Aug 1 |
1 |
| 75 |
20940192 | Association of DNA repair gene polymorphisms with response to platinum-based doublet chemotherapy in patients with non-small-cell lung cancer. | 2010 Nov 20 |
1 |
| 76 |
18575867 | ERCC1 expression and RAD51B activity correlate with cell cycle response to platinum drug treatment not DNA repair. | 2009 Mar |
1 |
| 77 |
18937971 | TP53, BCL-2 and BAX analysis in 199 ovarian cancer patients treated with taxane-platinum regimens. | 2009 Jan |
1 |
| 78 |
19150122 | Prognostic value and clinicopathological significance of p53 and PTEN in epithelial ovarian cancers. | 2009 Mar |
1 |
| 79 |
20719132 | [Prognostic Analysis of ERCC1, RRM1 and p53 Expressions in Postoperative Stage I-II Lung Cancer.]. | 2009 May 20 |
1 |
| 80 |
18172257 | Both germ line and somatic genetics of the p53 pathway affect ovarian cancer incidence and survival. | 2008 Jan 1 |
1 |
| 81 |
18193228 | 7-Chloro-6-piperidin-1-yl-quinoline-5,8-dione (PT-262), a novel synthetic compound induces lung carcinoma cell death associated with inhibiting ERK and CDC2 phosphorylation via a p53-independent pathway. | 2008 Oct |
3 |
| 82 |
18230133 | TP53 status and taxane-platinum versus platinum-based therapy in ovarian cancer patients: a non-randomized retrospective study. | 2008 Jan 29 |
10 |
| 83 |
18281754 | [Predictive markers for platinum-based chemotherapy]. | 2008 Feb |
1 |
| 84 |
18507046 | Loss of heterozygosity, microsatellite instability and TP53 gene status in ovarian carcinomas. | 2008 Mar-Apr |
1 |
| 85 |
17640298 | Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy. | 2007 Sep |
1 |
| 86 |
17686239 | [The predictive factors for the response to platinum/paclitaxel based first-line adjuvant chemotherapy in advanced ovarian cancer]. | 2007 May 8 |
1 |
| 87 |
16739339 | P53 gene status in patients with advanced serous epithelial ovarian cancer in relation to response to paclitaxel- plus platinum-based chemotherapy and long-term clinical outcome. | 2006 Jan-Feb |
1 |
| 88 |
16750013 | [Association of the responsiveness of advanced non-small cell lung cancer to platinum-based chemotherapy with p53 and p73 polymorphisms]. | 2006 Feb |
3 |
| 89 |
16127286 | p53 Gene status and response to topotecan-containing chemotherapy in advanced ovarian carcinoma. | 2005 |
2 |
| 90 |
16322298 | Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo. | 2005 Dec 1 |
4 |
| 91 |
14729645 | Molecular determinants of the cytotoxicity of platinum compounds: the contribution of in silico research. | 2004 Jan 1 |
1 |
| 92 |
15486204 | Differential recognition by the tumor suppressor protein p53 of DNA modified by the novel antitumor trinuclear platinum drug BBR3464 and cisplatin. | 2004 |
2 |
| 93 |
12570658 | Mechanisms controlling sensitivity to platinum complexes: role of p53 and DNA mismatch repair. | 2003 Feb |
2 |
| 94 |
12684687 | The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells. | 2003 May |
1 |
| 95 |
14513366 | Status of p53 phosphorylation and function in sensitive and resistant human cancer models exposed to platinum-based DNA damaging agents. | 2003 Dec |
2 |
| 96 |
12006509 | p53 mutations in leukemia and myelodysplastic syndrome after ovarian cancer. | 2002 May |
1 |
| 97 |
12093475 | JM216-, JM118-, and cisplatin-induced cytotoxicity in relation to platinum-DNA adduct formation, glutathione levels and p53 status in human tumour cell lines with different sensitivities to cisplatin. | 2002 Jun 1 |
1 |
| 98 |
12440809 | Molecular mechanisms of apoptosis and chemosensitivity to platinum and paclitaxel in ovarian cancer: biological data and clinical implications. | 2002 |
4 |
| 99 |
12468337 | Correlation of p53 immunostaining in primary and residual ovarian cancer at the time of positive second-look laparotomy and its prognostic role: a Southwest Oncology Group ancillary study. | 2002 Oct |
1 |
| 100 |
12478472 | Apoptosis and growth arrest induced by platinum compounds in U2-OS cells reflect a specific DNA damage recognition associated with a different p53-mediated response. | 2002 Dec |
3 |